PPLPHARMA - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.8
| Stock Code | PPLPHARMA | Market Cap | 23,163 Cr. | Current Price | 174 ₹ | High / Low | 221 ₹ |
| Stock P/E | 29.9 | Book Value | 58.2 ₹ | Dividend Yield | 0.08 % | ROCE | 12.1 % |
| ROE | 10.4 % | Face Value | 10.0 ₹ | DMA 50 | 165 ₹ | DMA 200 | 173 ₹ |
| Chg in FII Hold | 0.51 % | Chg in DII Hold | -0.07 % | PAT Qtr | 313 Cr. | PAT Prev Qtr | 151 Cr. |
| RSI | 56.0 | MACD | 5.22 | Volume | 25,73,075 | Avg Vol 1Wk | 23,26,425 |
| Low price | 132 ₹ | High price | 221 ₹ | PEG Ratio | 0.25 | Debt to equity | 0.12 |
| 52w Index | 47.3 % | Qtr Profit Var | 13.0 % | EPS | 5.27 ₹ | Industry PE | 31.6 |
📊 Optimal Buy Price (Intraday): ₹170–174 (near 50 DMA support at ₹165 and 200 DMA at ₹173)
🎯 Profit-Taking Levels: ₹180–185 (short-term resistance zone, below recent high ₹221)
🛡️ Stop-Loss / Loss Protection: ₹164–166 (below intraday support zone)
⏱️ Exit Strategy (If Already Holding): Exit if price fails to sustain above ₹166 with weakening volume, or book profits if RSI approaches 58–60 and momentum flattens. Extend trades only if breakout above ₹185–190 is confirmed with strong intraday volume.
---
### Positive
- EPS at ₹5.27 supports valuation strength.
- PEG ratio (0.25) indicates attractive growth-adjusted valuation.
- PAT improved sequentially (₹151 Cr. → ₹313 Cr.), showing strong earnings recovery.
- Current price (₹174) trading above both DMA 50 (₹165) and DMA 200 (₹173), confirming technical support.
- MACD positive (5.22), supporting bullish bias.
- Volume (25.7 lakh) above weekly average (23.2 lakh), providing strong intraday liquidity.
- FII holding increased (+0.51%), reflecting foreign investor confidence.
### Limitation
- P/E (29.9) slightly below industry average (31.6), showing fair valuation but limited upside.
- Dividend yield at 0.08% is negligible.
- ROCE (12.1%) and ROE (10.4%) remain moderate compared to peers.
- RSI at 56.0 is neutral, limiting momentum.
- Sequential PAT growth only modest (+13%), showing earnings volatility.
### Company Negative News
- DII holding reduced (-0.07%), showing domestic institutional caution.
- Modest quarterly profit variation (+13%) limits upside momentum.
### Company Positive News
- PAT doubled sequentially, highlighting operational resilience.
- FII holding increased, supporting sentiment.
- EPS growth supports valuation strength.
### Industry
- Pharma sector benefits from defensive demand and long-term growth drivers.
- Industry PE at 31.6 is slightly higher than PPLPHARMA’s, showing fair valuation alignment.
### Conclusion
PPLPHARMA is a moderately strong intraday candidate with improving fundamentals and bullish technical signals. Best suited for disciplined trades between ₹170–185 with strict stop-loss at ₹166. Avoid aggressive positions unless breakout above ₹190 is confirmed with strong volume; risk remains moderate due to limited dividend yield and modest efficiency ratios.
Would you like me to extend this into a peer benchmarking HTML overlay comparing PPLPHARMA’s intraday setup against Cipla, Lupin, and Sun Pharma for sector-relative positioning?